These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 11772257)

  • 61. Phosphodiesterase 4-selective inhibition: novel therapy for the inflammation of COPD.
    Jeffery P
    Pulm Pharmacol Ther; 2005; 18(1):9-17. PubMed ID: 15607122
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The potential of PDE4 inhibitors in respiratory disease.
    Spina D
    Curr Drug Targets Inflamm Allergy; 2004 Sep; 3(3):231-6. PubMed ID: 15379590
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
    Karish SB; Gagnon JM
    Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669
    [TBL] [Abstract][Full Text] [Related]  

  • 64. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.
    Sanz MJ; Cortijo J; Morcillo EJ
    Pharmacol Ther; 2005 Jun; 106(3):269-97. PubMed ID: 15922015
    [TBL] [Abstract][Full Text] [Related]  

  • 65. COPD, inflammation and its modulation by phosphodiesterase 4 inhibitors: time to look beyond the FEV1.
    Celli B
    Chest; 2006 Jan; 129(1):5-6. PubMed ID: 16424403
    [No Abstract]   [Full Text] [Related]  

  • 66. Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD.
    Huang Z; Mancini JA
    Curr Med Chem; 2006; 13(27):3253-62. PubMed ID: 17168849
    [TBL] [Abstract][Full Text] [Related]  

  • 67. AWD 12-281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis.
    Bäumer W; Gorr G; Hoppmann J; Ehinger AM; Rundfeldt C; Kietzmann M
    J Pharm Pharmacol; 2003 Aug; 55(8):1107-14. PubMed ID: 12956900
    [TBL] [Abstract][Full Text] [Related]  

  • 68. PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6).
    Cheung YF; Kan Z; Garrett-Engele P; Gall I; Murdoch H; Baillie GS; Camargo LM; Johnson JM; Houslay MD; Castle JC
    J Pharmacol Exp Ther; 2007 Aug; 322(2):600-9. PubMed ID: 17519386
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.
    Dastidar SG; Rajagopal D; Ray A
    Curr Opin Investig Drugs; 2007 May; 8(5):364-72. PubMed ID: 17520865
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Roflumilast: a selective phosphodiesterase 4 inhibitor.
    Christie P
    Drugs Today (Barc); 2005 Oct; 41(10):667-75. PubMed ID: 16389409
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A role for phosphodiesterase type-4 inhibitors in COPD?
    Johnson DC
    Lancet; 2001 Jul; 358(9278):256-7. PubMed ID: 11498207
    [No Abstract]   [Full Text] [Related]  

  • 72. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
    Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
    Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
    [TBL] [Abstract][Full Text] [Related]  

  • 73. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.
    Griswold DE; Webb EF; Badger AM; Gorycki PD; Levandoski PA; Barnette MA; Grous M; Christensen S; Torphy TJ
    J Pharmacol Exp Ther; 1998 Nov; 287(2):705-11. PubMed ID: 9808700
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of cyclosporin A and cilomilast on activated canine, murine and human keratinocytes.
    Bäumer W; Kietzmann M
    Vet Dermatol; 2007 Apr; 18(2):107-14. PubMed ID: 17355425
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
    Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?
    Giembycz MA
    Drugs; 2000 Feb; 59(2):193-212. PubMed ID: 10730545
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The efficacy and safety of cilomilast in COPD. Forward.
    Agusti A
    Drugs; 2008; 68 Suppl 2():1-2. PubMed ID: 19105584
    [No Abstract]   [Full Text] [Related]  

  • 78. Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD.
    Jones NA; Leport M; Holand T; Vos T; Morgan M; Fink M; Pruniaux MP; Berthelier C; O'Connor BJ; Bertrand C; Page CP
    Pulm Pharmacol Ther; 2007; 20(1):60-8. PubMed ID: 16427796
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The role of theophylline and phosphodiesterase4 isoenzyme inhibitors as anti-inflammatory drugs.
    Spina D; Landells LJ; Page CP
    Clin Exp Allergy; 1998 Aug; 28 Suppl 3():24-34. PubMed ID: 9756183
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells.
    Meyers JA; Taverna J; Chaves J; Makkinje A; Lerner A
    Clin Cancer Res; 2007 Aug; 13(16):4920-7. PubMed ID: 17699872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.